Long-term Consequences, Chances of Re-infection, and Outcomes among Cases Recovered with Severe COVID-19 at a Tertiary Care Centre in Central India
Downloads
COVID-19 has a wide disease spectrum. Different presentations may be seen in different people, with uncertain long-term fate. The amount and longevity of immunity provided among the infected also vary from person to person which might in turn affect the chances of re-infection. Current study tries to uncover the incidence, disease severity and outcomes amongst those who have been previously hospitalized for COVID-19. A prospective cohort study where all patients admitted to intensive care facility at the tertiary care center were followed up for any occurrences of re-infection for more than one year. All cases were followed up telephonically and at scheduled visits to the hospital by trained personnel. A total of 410 cases with a mean age of 59.8 years, including 310 (75.6%) males and 100 (24.4%) females. Among these 410 patients 287 remained alive till the end of study period. Re-infection rates among recovered ICU admitted seriously ill patients were 1.4% whereas the rate of ICU re-admission due to COVID-19 re-infection was only 0.7%. Re-infection among female was 1.1% whereas in male was 1.5%. ICU readmission rate among female was 1.1% while in male was 0.5% only. The chances of re-infection in female were seen less than that in males, but the severity of re-infection in females was found to be higher. COVID-19 re-infection in previously severely infected COVID-19 patient is not so common. The chances of a severe disease among such cases are even rarer.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 Mar 28;395(10229):1054–62.
Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020 Feb 14;8(1):1–8.
Cortinovis M, Perico N, Remuzzi G. Long-term follow-up of recovered patients with COVID-19. Lancet. 2021;397(10270):173–5.
Hall V, Foulkes S, Charlett A, Atti A, Monk EJ, Simmons R, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. Medrxiv. 2021.
Galanti M, Shaman J. Direct Observation of Repeated Infections With Endemic Coronaviruses. J Infect Dis. 2020;jiaa392.
Mukherjee A, Anand T, Agarwal A, Singh H, Chatterjee P, Narayan J, et al. SARS-CoV-2 re-infection: development of an epidemiological definition from India. Epidemiology & Infection. 2021;149.
Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother. :1–6.
Jain VK, Iyengar K, Garg R, Vaishya R. Elucidating reasons of COVID-19 re-infection and its management strategies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021 May 1;15(3):1001-6.
Perez G, Banon T, Gazit S, Moshe SB, Wortsman J, Grupel D, Peretz A, Tov AB, Chodick G, Mizrahi-Reuveni M, Patalon T. A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report. MedRxiv. 2021.
Harnath AT, Payne BA, Duncan CJ. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. Journal of Infection. 2021 Apr 1;82(4):e29-30.
Shastri J, Parikh S, Agrawal S, Chatterjee N, Pathak M, Chaudhary S, Sharma C, Kanakan A, Srinivasa Vasudevan J, Maurya R, Fatihi S. Clinical, serological, whole genome sequence analyses to confirm SARS-CoV-2 reinfection in patients from Mumbai, India. Frontiers in medicine. 2021:215.
Singh PP, Tamang R, Shukla M, Pathak A, Srivastava A, Gupta P, Bhatt A, Shrivastava AK, Upadhyay SK, Singh A, Maurya S. Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations. medRxiv. 2021 Jan 1.
Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clinical Microbiology and Infection. 2021 Mar 1;27(3):315–8.
Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020 Nov 26;10(1):20692.
To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clinical Infectious Diseases [Internet]. 2020 Aug 25 [cited 2021 Jul 31];(ciaa1275). Available from: https://doi.org/10.1093/cid/ciaa1275
Updated Clinical Management Protocol for COVID 19 dated 03072020.pdf [Internet]. [cited 2022 July 13]. Available from: https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf.
Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis. Journal of Medical Virology. 2022;94(1):44–53.
Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 re-infections. J Med Virol. 2021; 93(3): 1599- 1604.
Ren X, Ren X, Lou J, et al. A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR. EClinicalMedicine. 2021; 34: 100839.
Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infect Dis. 2021; 53(5): 315- 324.
Rawat SK, Asati AA, Jain A, Mishra N, Ratho RK Covid-19 associated hepatitis in children (CAH-C) during the second wave of SARS-CoV-2 infections in Central India: is it a complication or transientphenomenon?medRxiv2022. https://www.medrxiv.org/content/10.1101/2021.07.23.21260716v7
Azam M, Sulistiana R, Ratnawati M, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020; 10(1):20692.
Chakravarty D, Nair SS, Hammouda N, et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol. 2020; 3(1): 1- 2.
Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy | Infectious Diseases | JAMA Internal Medicine | JAMA Network [Internet]. [cited 2021 Nov 15]. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2780557
Hall VJ, Foulkes S, Charlett A, et al; SIREN Study Group. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459-1469.
Copyright (c) 2022 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
